BAY-364

Cat. No.:	HY-150239
CAS No.:	2097610-30-3
Molecular Formula:	$C_{23}H_{19}N_3O_4$
Molecular Weight:	401.41
Target:	DNA/RNA Synthesis
Pathway:	Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	BAY-364 (BAY-299N) is an inhibitor of the second bromine domain in TAF1. BAY-364 inhibits the TAF1 of Kasumi-1 cells, CD34$^+$ cells and K562 cells with IC_{50} values of 1.0 μM, 10.4 μM and 10.0 μM respectively[1].
In Vitro	BAY-364 (0.1-100 μM; 3 d) inhibits the growth of Kasumi-1 cells, CD34$^+$ cells and K562 cells[1]. BAY-364 (72 h) decreases the expression of ID1, MYC and TAF1 but insignificantly affect the expression of AE in the Kasumi-1 cells[1]. BAY-364 (10 μM; 2 d) reduces colony formation in AE9a$^+$ cells[1]. BAY-364 (2 μM; 48 h and 72 h) has insignificant effect on the cell cycle of K562 cells[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis[2]

Cell Line:	K562 cells.
Concentration:	2 μM.
Incubation Time:	48 h and 72 h.
Result:	Had insignificant effect on the cell cycle.

REFERENCES

[1]. Xu Y, et al. TAF1 plays a critical role in AML1-ETO driven leukemogenesis. Nat Commun. 2019 Oct 29;10(1):4925.

[2]. Garcia-Carpizo V, et al. Therapeutic potential of TAF1 bromodomains for cancer treatment[J]. bioRxiv, 2018: 394254.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA